MedTrace Logo

Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer

NCT04612907 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2024-02-28

No results posted yet for this study

Summary

de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.

Conditions

Interventions

RADIATION

Moderate hypo-fractionation

Patients will receive four weeks of radiotherapy

RADIATION

Ultra-hypo-fractionation

Patients will receive two and a half weeks of radiotherapy

Sponsors & Collaborators

  • Umeå University

    lead OTHER

Principal Investigators

  • Camilla of T Karlsson · Cancercentrum Umeå University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-31
Primary Completion
2026-06-30
Completion
2032-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04612907 on ClinicalTrials.gov